Previous 10 | Next 10 |
2024-06-21 09:12:53 ET More on Solid Biosciences Buy Solid Biosciences: Unpacking Its Main Value Driver Solid Biosciences gets FDA rare pediatric disease status for DMD therapy William Blair starts Solid Biosciences at outperform Seeking Alpha’s Quant ...
2024-06-21 08:15:07 ET Goldman Sachs analyst issues BUY recommendation for SRPT on June 21, 2024 07:05AM ET. The previous analyst recommendation was Buy. SRPT was trading at $123.5 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current a...
2024-06-21 05:30:35 ET More on related stocks: Smith & Wesson Brands, Inc. (SWBI) Q4 2024 Earnings Call Transcript Asana: Don't Buy This Dip, Part 2 Asana, Inc. (ASAN) Q1 2025 Earnings Call Transcript Asana reiterates guidance, unveils $150M buyback ...
2024-06-20 20:30:02 ET Morgan Stanley analyst issues OVERWEIGHT recommendation for SRPT on June 20, 2024 07:15PM ET. The previous analyst recommendation was Overweight. SRPT was trading at $123.5 at issue of the analyst recommendation. The overall analyst consensus : BUY...
2024-06-20 17:31:25 ET More on Sarepta Therapeutics Sarepta Therapeutics: Navigating Elevidys Upside Potential Sarepta Therapeutics, Inc. (SRPT) Q1 2024 Earnings Call Transcript Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy Sarepta gains aft...
– FDA grants traditional approval to ELEVIDYS for ambulatory Duchenne patients – FDA grants accelerated approval to ELEVIDYS for non-ambulatory Duchenne patients – Sarepta will host an investor conference call on June 21, 2024, at 8:30 a.m. ET ...
2024-06-17 13:44:12 ET Summary Capricor Therapeutics, Inc.'s rolling BLA submission of CAP-1002 for the treatment of patients with DMD, expected in Q3 of 2024. Top-line results from Cohort A of the phase 3 HOPE-3 study, using CAP-1002 for the treatment of patients with DMD, expect...
2024-06-17 13:29:18 ET Summary Sarepta Therapeutics submitted a request to the FDA for label expansion of Elevidys, with a response expected by June 21st. Roche initiated the process for Elevidys marketing authorization application in Europe, expected to be completed by H1 2024. ...
2024-06-16 11:15:16 ET Summary Entrada Therapeutics' stock has dropped significantly due to FDA holds on two IND applications, but recent insider buying suggests potential upside. The company's EEV platform aims to target malady-inducing dysfunction inside cells with high proficie...
2024-06-14 15:00:00 ET More on the markets SPY Is Sub-Optimal For Long-Term Diversified Investors S&P 500 Peaks And VIX Valleys As Market Signals Going Into June, SPY Or VXF, Which Is The Better Buy? (Technical Analysis) Citi says ETFs will engulf U.S. as...
News, Short Squeeze, Breakout and More Instantly...
Sarepta Therapeutics Inc. Company Name:
SRPT Stock Symbol:
NASDAQ Market:
Sarepta Therapeutics Inc. Website:
Rick Barry appointed Executive Chairman of the Board Remi Barbier resigns as President and CEO and from the Board of Directors Cassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Boa...
2024-07-08 12:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...